Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.

ABSTRACT:

Background and purpose

A subgroup of salivary duct carcinoma (SDC) harbor overexpression of the androgen receptor (AR), and co-occurring mutations in the HRAS- and PIK3CA-genes. The impact of genomic complexity on targeted treatment strategies in advanced cancer is unknown.

Materials and methods

We analyzed molecular and clinical data from an institutional molecular tumor board (MTB) to identify AR+, HRAS/PIK3CA co-mutated SDC. Follow-up was performed within the MTB registrational study or retrospective chart review after approval by the local ethics committee. Response was assessed by the investigator. A systematic literature search was performed in MEDLINE to identify additional clinically annotated cases.

Results

4 patients with AR+ H

SUBMITTER: Rieke DT 

PROVIDER: S-EPMC10325704 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature